PUBLISHER: DataM Intelligence | PRODUCT CODE: 1297790
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1297790
The Global Dermatology Drugs Market size was worth US$ 18,684.8 million in 2022 and is estimated to reach US$ 40,830.9 million by 2030, growing at a CAGR of 10.5% during the forecast period (2023-2030).
Dermatology can help people overcome acne, inspect skin blemishes, get skin cancer screenings, treat eczema and psoriasis, and much more. When it comes to things happening under the surface, your skin can tell you everything.
The frequent introduction of new and customer-focused goods is expected to have a greater impact on the global dermatological medicines business. For example, Eli Lilly's psoriasis treatment has received approval from India's DCGI, allowing the business to access the Indian dermatological market. Marketing methods such as website launches, TV and social media commercials promoting campaign awareness, and others will also aid in the market's development over the forecast period.
The increasing costs associated with these medications hinder market expansion. Many market participants make large investments in the development of new pharmaceuticals in order to speed up the recovery process, which raises the cost. As a result, this issue impedes market expansion because treatment alternatives are not practical for all income groups.
COVID-19 has a terrifying effect on dermatological medications. Many current clinical trials for dermatological treatments were interrupted by the pandemic, affecting market growth as many trials were discontinued or postponed due to safety concerns, limited patient visits to clinics, and prioritisation of resources for COVID-19 research. As a result, medication research and clearance schedules have been pushed back.
Also Patient visits to dermatological clinics were reduced as a result of the epidemic, and elective operations were postponed. As a result, some people may have had delayed diagnosis and treatment for dermatological problems. This delay may have an influence on illness management and overall results.
The global dermatology drugs market is segmented based on Application , Drug class and End user
Acne is expected to grow at a significant CAGR during the forecast period, owing to an increase in the number of market participants offering improved products internationally. Acne prevalence is also increasing, particularly among young people, which is a key factor contributing to the expansion of this category. Furthermore, the availability of a wide selection of acne products at retail pharmacies, as well as the convenience of access, are fueling the development of this market.
Northa america has been dominating region for dermatology drugs market because of the rising incidence of dermatological infections. North America accounted for the majority of the market share of 38.7%. Another key aspect contributing to the region's growth is the presence of big businesses along with new launches. North America also possesses the most recent technology advances in R&D. This, together with increased dermatological product sales, is likely to fuel growth throughout the projection period. Furthermore, Asia Pacific is expected to have the highest CAGR due to increased public knowledge about the care and management of acne and other disorders.
The major global players include: Leo Pharma, Allergan, Amgen Inc. GI Dermatics Sanofi Merck & Co. Pfizer, AbbVie, Bausch Health, and Novartis.
The global dermatology drugs market report would provide approximately 92 tables, 108 figures and 195 pages.
LIST NOT EXHAUSTIVE